The company announced a merger agreement with Freenome Holdings, Inc. in December 2025, which led to a 20% surge in its share price.

• On December 5, 2025, Perceptive Capital Solutions Corp entered into a Business Combination Agreement with Freenome Holdings, Inc., subject to customary closing conditions and risks [N1][S1].
• Following the announcement of the merger deal with Freenome, the company’s shares surged 20% on the same day [N1].

The company’s focused strategy on healthcare and life sciences sectors leverages the management team’s expertise and network, potentially enabling identification of attractive acquisition targets. The recent merger agreement with Freenome, a healthcare company, represents a significant milestone that could enhance the company’s profile and access to public capital markets. The management’s track record with previous SPACs and investments in healthcare companies may provide operational and strategic advantages in executing the business combination.

The company has not generated operating revenues and remains dependent on completing its initial business combination to realize value. Its liquidity position as of June 30, 2026, is limited, with a current ratio of 0.2 and no reported cash equivalents, which may constrain operational flexibility. Risks include potential conflicts of interest due to management’s affiliations with other investment vehicles, uncertainties related to international trade policies and tariffs that could impact target businesses, and the possibility that the business combination with Freenome may not be consummated. Additionally, shareholder redemption rights and market conditions may affect the transaction’s structure and outcomes.

The company’s moat is primarily derived from its management team’s extensive experience and network in the healthcare investment sector, particularly through Perceptive Advisors, which manages significant assets and has a strong reputation in life sciences and medical technology investments. This network provides access to a broad universe of potential acquisition targets and industry relationships that may not be readily available to other SPACs. The focused acquisition strategy targeting companies with scientific or competitive advantages and readiness to be public further supports its competitive positioning.

• Liquidity Risk: The company reported a current ratio of 0.2 and no cash equivalents as of June 30, 2026, indicating limited liquidity which may affect its ability to fund operations or complete the business combination without additional financing [S2].
• Business Combination Completion Risk: The initial business combination with Freenome is subject to customary closing conditions and risks; failure to consummate the transaction within the prescribed timeframe may lead to liquidation and redemption of public shares [S1][S2].
• Conflicts of Interest: Management and sponsor affiliations with other investment vehicles and SPACs may create conflicts of interest in selecting and completing the business combination [S1].
• Trade Policy and Tariff Risks: Changes in international trade policies, tariffs, and geopolitical tensions may adversely affect the ability to consummate the business combination or impact the operations and financial results of the post-business combination company [S2].
• Redemption Rights Impact: Public shareholders’ redemption rights may affect the capital structure and financing of the business combination, potentially leading to dilution or restructuring of the transaction [S2].

• Perceptive Capital Solutions Corp is a blank check company incorporated in March 2024 as a Cayman Islands exempted company formed to effect a business combination with one or more businesses, focusing on healthcare or healthcare-related industries, particularly life sciences and medical technology sectors in North America and Europe [S1].
• The company completed its Initial Public Offering (IPO) in June 2024, raising $86.25 million placed in a trust account for the benefit of public shareholders and the underwriter [S1].
• The management team has extensive investment experience in healthcare, led by executives affiliated with Perceptive Advisors, a life sciences focused investment firm with over $9.5 billion in assets under management as of December 31, 2025 [S1].
• The company has not generated operating revenues to date and does not expect to until consummation of its initial business combination [S1].
• Perceptive Capital Solutions has entered into a Business Combination Agreement with Freenome Holdings, Inc. on December 5, 2025, subject to customary closing conditions and risks [S1].
• The company’s acquisition strategy targets companies with scientific or competitive advantages, readiness to be public, strong management, significant growth opportunities, and unrecognized value in the healthcare sector [S1].
• As of June 30, 2026, the company reported current assets of $742,154 and current liabilities of $3,628,077, resulting in a current ratio of 0.2 and a cash ratio of 0, indicating limited liquidity [S2].
• The company reported a net loss of $114,943 for the quarter ended June 30, 2026 [S2].
• Public shareholders have redemption rights under certain conditions, including if the initial business combination is not consummated within 24 months (or 36 months if extended) from the IPO closing [S2].
• The company faces risks related to international trade policies and tariffs that may affect its ability to consummate a business combination or impact the operations of a post-business combination company [S2].
• The company’s management and sponsor may have conflicts of interest due to affiliations with other investment vehicles and SPACs [S1].
• The company’s shares surged 20% following the announcement of the merger deal with Freenome on December 5, 2025 [N1].